Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020114355 - RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF

Publication Number WO/2020/114355
Publication Date 11.06.2020
International Application No. PCT/CN2019/122446
International Filing Date 02.12.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
C07K 19/00 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/13 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
13Immunoglobulins
C12N 15/62 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/71
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
71for growth factors; for growth regulators
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
Applicants
  • IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) CO., LTD [CN]/[CN]
Inventors
  • TIAN, Wenzhi
  • LI, Song
Agents
  • SHENZHEN SERMON PATENT FIRM
Priority Data
62/774,84903.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) RECOMBINANT PROTEIN TARGETING PD-L1 AND VEGF
(FR) PROTÉINE DE RECOMBINAISON CIBLANT PD-L1 ET VEGF
Abstract
(EN)
Provided is a recombinant protein containing 1) an anti-PD-L1 antibody heavy chain and an anti-PD-L1 antibody light chain, which two are linked by a disulfide bond to bind PD-L1, and 2) an extracellular Ig-like domain of a vascular epithelial growth factor receptor (VEGFR), linked via a linker to the N-terminus or C-terminus of the heavy chain or the light chain, wherein the recombinant protein is capable of binding PDL1, VEGF and Fc receptor simultaneously. Further provided are a recombinant antibody containing two said recombinant proteins, a polynucleotide encoding the recombinant protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein, a pharmaceutical composition comprising the recombinant protein and a method for treating a disease caused by over expression of VEGF and/or PD-L1 using the recombinant protein.
(FR)
L'invention concerne une protéine de recombinaison contenant 1) une chaîne lourde d'anticorps anti-PD-L1 et une chaîne légère d'anticorps anti-PD-L1, les deux étant liées par une liaison disulfure pour se lier à PD-L1, et 2) un domaine de type Ig extracellulaire d'un récepteur du facteur de croissance épithéliale vasculaire (VEGFR), lié par l'intermédiaire d'un lieur à l'extrémité N-terminale ou C-terminale de la chaîne lourde ou de la chaîne légère, la protéine de recombinaison étant capable de se lier simultanément au récepteur PDL1, VEGF et Fc. L'invention concerne également un anticorps de recombinaison contenant lesdites deux protéines de recombinaison, un polynucléotide codant pour la protéine de recombinaison, un vecteur d'expression contenant le polynucléotide, un procédé de production de la protéine de recombinaison, une composition pharmaceutique comprenant la protéine de recombinaison et une méthode de traitement d'une maladie provoquée par une sur-expression de VEGF et/ou de PD-L1 à l'aide de la protéine de recombinaison.
Latest bibliographic data on file with the International Bureau